Revance Therapeutics Investor Presentation — November 2019

Document content

Investor presentation

NOVEMBER 2019Forward -Looking Statements / Safe Harbor / Market Data

This presentation contains forward -looking statements, including forward -statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to: financial metrics, the

process and timing of, and ability to complete, current and anticipated future clinical development of our investigational pr odu ct candidates, including anticipated near -term milestones; the initiation, enrollment,

design, timing and outcome of our clinical trials, including for the treatment of glabellar (frown) lines, forehead lines, la teral canthal lines (crow’s feet), cervical dystonia, plantar fasciitis, adult upper limb spasticity

and chronic migraine, relating to DaxibotulinumtoxinA for Injection (DAXI); and related results and reporting of such results and statements; timing of our potential BLA submissio n and regulatory determinations

regarding the potential label for DAXI to treat glabellar (frown) lines and commercial potential of our drug candidates, stat us of commercial collaborations, including regulatory approval and related milestones and

potential receipt of royalties under our license agreement with Fosun Pharma and collaboration agreement with Mylan’s continuation decision and the timing thereof; our ability to obtain, and timi ngrelating to,

regulatory approval with respect to our drug candidates; our ability to commercialize and launch, and related timelines relat ing to, our product candidates; the potential aesthetic, therapeutic and economic benefits

and value of our product candidates and our technologies; demand for our product candidates and drivers of demand; market siz e, adoption rate and potential revenue; growth opportunities and product pipeline;

our business strategy, timeline and other goals and market for our anticipated products, plans and prospects; our ability to leverage our investment in our development and manufacturing platform; our commercial

and intellectual property strategy; and our financial and operating projections, including cash and operating expense forecas t.

Forward -looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our expectations. These risks and uncertainties include, but are not limited to: the outcome,

cost and timing of our product development activities and clinical trials; the uncertain clinical development process, includ ing the risk that clinical trials may not have an effective design or generate positive results, or

that positive results would assure regulatory approval or commercial success of our product candidates; that we may not obtai n the anticipated financial and other benefits of the license agreement with Fosun